Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 1 
CLINICAL STUDY 
PROTOCOL  
Study Number:  PyL 2301 
Study Title:  A PrOspective Phase 2/3 Multi- Center Study of 18F-DCFPyL PET/CT 
Imaging  in Patients with P Rostate Cancer: Examination of Diagnostic 
AccuracY  (OSPREY)  
Product Name:  18F-DCFPyL INJECTION (PyL)  
IND Number  129,952 
Sponsor:  Progenics Pharmaceuticals, Inc.  
One World Trade Center 
47th Floor, Suite J 
New York, NY 10007   (646) 975-2500
Protocol Version  Original:  July 12, 2016 
Amendment 1: September 16, 2016 
Amendment 2: November 6, 2017
[STUDY_ID_REMOVED] 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by 
you, your staff, and the applicable Institutional Review Board/Independent Ethics committee.  Your acceptance 
of this document constitutes agreement that you will not disclose the information contained herein to others 
without prior written authorization from Progenics Pharmaceuticals, Inc.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 2 
INVESTIGATOR’S AGREE MENT 
I acknowledge that I  have read the attached protocol and agree that it contains all information 
necessary to conduct the study and agree to conduct the study as outlined within . 
I agree to comply with all stated provisions , including but not limited to regulations/guidelines 
relevant to the conduct of human trials, as set forth in Title 21 of the Code of Federal 
Regulations (CFR), and Good Clinical Practices as set forth by International Conference on 
Harmonisatio n of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH).    
I will not initiate the study until I have obtained written approval from the appropriate Institutional Review Board (IRB)/Independent Ethics Committee (IEC).  I will obtain written informed consent from all study participants prior to performing any screening procedures. 
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol.  I understand and acknowledge that confidential information includes, but is not limited to, (i) the study protocol, (ii) the data derived from the study, and (iii) my impressions 
of the progress or results of the study.  I further agree that I will not use such Confidential Information for any purpose other than the evaluation or conduct of the clinical investigation.   
I certify that I have not been disqualified by any regulatory authority or otherwise disqualified 
from serving as a principal investigator.  I a lso agree that in the event I become debarred, I shall 
immediately cease all activities relating to the study.  
I am not presently, nor will I be during the term of the study, a consultant or advisor to any division of any financial or securities firm.  
I understand that my signature on a case report form indicates that the data therein have been 
reviewed and are deemed to be complete, accurate, and acceptable to me.  
Printed Name of  Principal Investigator 
Signature of Principal Investigator  
Date  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 4 
PROCEDURES IN CASE OF EMERGENCY  
Table 1: Emergency Contact Information 
Role in Study  Name E-mail and Telephone
Number
Clinical Project Manager  
Clinical Study Leader  
Responsible Physician 

Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 5 
1. T ABLE OF CONTENTS
2. LIST OF ABBREVIATION S AND DEFI NITIONS OF  TERMS ...............................9  
3. INTRODUCTION  ......................................................................................................12  
3.1. Background Information .............................................................................................12  
3.2. Rationale for Developing Prostate Cancer Imaging Agents .......................................12  
3.3. Targeting PSMA for Prostate Cancer Detection  ........................................................13  
3.4. 18F-DCFPyL  ................................................................................................................15  
3.5. Rationale for Dose Selection  ......................................................................................16  
4. TRIAL OBJECTIVES AND PURPOSE  ....................................................................17  
4.1. Primary Objective  .......................................................................................................17  
4.2. Secondary Objectives  .................................................................................................17  
4.3. Exploratory Objectives ...............................................................................................17  
5. TRIAL ENDPOINTS  .................................................................................................18  
5.1. Primary Endpoints ......................................................................................................18  
5.2. Secondary Endpoints ..................................................................................................18  
5.3. Exploratory Endpoints ................................................................................................18  
6. INVESTIGATIONAL PLAN  .....................................................................................19  
6.1. Overall Study Design  ..................................................................................................19  
6.2. Number of Subjects ....................................................................................................19  
6.3. Treatment Assignment  ................................................................................................19  
6.4. Dose Adjustment Criteria  ...........................................................................................20  
6.5. Study Duration  ............................................................................................................20  
6.6. Safety Monitoring .......................................................................................................20  
6.7. Criteria for Study Termination  ...................................................................................20  
7. SELECTION AND WITHDRAWAL OF SUBJECTS  ..............................................23  
7.1. Subject Inclusion Criteria  ...........................................................................................23  
7.2. Subject Exclusion Criteria  ..........................................................................................23  
7.3. Subject Withdrawal Criteria  .......................................................................................24  
8. TREATMENT OF SUBJECTS ..................................................................................24  
8.1. Description of Study Drug ..........................................................................................24  
8.2. Concomitant Medications and Procedures .................................................................25  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 6 
8.3. Treatment Compliance  ................................................................................................25  
8.4. Randomization and Blinding ......................................................................................25  
9. STUDY DRUG MATERIALS  AND MANAGE MENT  ...........................................25  
9.1. Study Drug  ..................................................................................................................25  
9.2. Restrictions  .................................................................................................................25  
9.2.1.  Food and Fluid Intake  .................................................................................................25  
9.2.2.  Activity  .......................................................................................................................26  
9.3. Study Drug Packaging and Labeling  ..........................................................................26  
9.4. Study Drug Storage  .....................................................................................................26  
9.5. Study Drug Preparation  ..............................................................................................26  
9.6. Administration  ............................................................................................................26  
9.7. Study Drug Accountability .........................................................................................27  
9.8. Study Drug Handling and Disposal ............................................................................27  
10. ASSESSMENT OF EFFICA CY ................................................................................28  
10.1.  Image Acquisition  .......................................................................................................28  
10.1.1.  18F-DCFPyL PET/CT (all cohorts)  .............................................................................28  
10.1.2.  Bone Scan (all cohorts) ...............................................................................................28  
10.1.3.  CT or MRI (all cohorts) ..............................................................................................28  
10.1.4.  Biopsy Guided Imaging (cohort B only) ....................................................................28  
10.2.  Image Interpretation ....................................................................................................28  
10.3.  Prostatectomy and Lymphadenectomy  .......................................................................29  
10.4.  Interventional Radiology ............................................................................................29  
10.5.  Biopsy and Surgical Pathology ...................................................................................29  
10.6.  Pharmacokinetics  ........................................................................................................29  
11. ASSESSMENT OF SAFETY  .....................................................................................31  
11.1.  Safety Parameters  .......................................................................................................31  
11.1.1.  Demographic/Medical History  ...................................................................................31  
11.1.2.  Vital Signs  ..................................................................................................................31  
11.1.3.  Weight and Height ......................................................................................................31  
11.1.4.  Electrocardiogram (ECG)  ...........................................................................................31  
11.1.5.  Laboratory Assessments  .............................................................................................31  
11.1.5.1.  Hematology, Blood Chemistry, PSA and Testosterone..............................................31  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 7 
11.2.  Adverse and Serious Adverse Events .........................................................................32  
11.2.1.  Definition of Adverse Events .....................................................................................32  
11.2.1.1.  Adverse Event (AE)  ....................................................................................................32  
11.2.1.2.  Serious Adverse Event (SAE) ....................................................................................32  
11.3.  Relationship to Study Drug ........................................................................................33  
11.4.  Recording Adverse Events .........................................................................................33  
11.5.  Reporting Serious Adverse Events .............................................................................34  
12. STATISTICS  ..............................................................................................................34  
12.1.  Sample Size  ................................................................................................................34  
12.2.  Analysis Populations ..................................................................................................35  
12.2.1.  Screened Subjects  .......................................................................................................35  
12.2.2.  Safety Set  ....................................................................................................................35  
12.2.3.  Evaluable Set  ..............................................................................................................35  
12.2.4.  Per Protocol Set  ..........................................................................................................36  
12.2.5.  PK Evaluable Set  ........................................................................................................36  
12.3.  Endpoints and Derivations ..........................................................................................36  
12.3.1.  Sensitivity, Specificity, PPV, and NPV ......................................................................36  
12.3.2.  Lesions Per Subject .....................................................................................................37  
12.3.3.  Change from Baseline  .................................................................................................37  
12.3.4.  Pre-Treatment and Concomitant Medications ............................................................37  
12.3.5.  Treatment -Emergent Adverse Events  .........................................................................37  
12.4.  Missing Data  ...............................................................................................................37  
12.5.  Analyses  ......................................................................................................................37  
12.5.1.  Subject Characteristics  ................................................................................................37  
12.5.2.  Efficacy Analysis  ........................................................................................................38  
12.5.2.1.  Primary Endpoint ........................................................................................................38  
12.5.2.2.  Secondary Endpoints ..................................................................................................38  
12.5.2.3.  Exploratory Analyses ..................................................................................................39  
12.5.3.  Safety  ..........................................................................................................................39  
12.5.3.1.  Exposure .....................................................................................................................39  
12.5.3.2.  Adverse Events  ...........................................................................................................40  
12.5.3.3.  Clinical Laboratory  .....................................................................................................40  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 8 
12.5.3.4.  ECG  ............................................................................................................................40  
12.5.3.5.  Vital Signs  ..................................................................................................................40  
12.5.4.  Pharmacokinetics  ........................................................................................................40  
13. DIRECT ACCESS TO SOU RCE DATA/ DOCUMENTS .........................................40  
13.1.  Study Monitoring ........................................................................................................40  
13.2.  Audits and Inspections ................................................................................................41  
14. ETHICS  ......................................................................................................................42  
14.1.  Good Clinical Practice (GCP), Laws and Regulations ...............................................42  
14.2.  Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 
Approval .....................................................................................................................42  
14.3.  Written Informed Consent ..........................................................................................42  
14.4.  Subject Confidentiality  ...............................................................................................43  
14.5.  Financial Disclosure  ...................................................................................................43  
15. DATA HANDLING AND RECORDKEEPING  .......................................................43  
15.1.  Case Report Forms and Study Records  ......................................................................43  
15.2.  Inspection of Records .................................................................................................43  
15.3.  Retention of Records ..................................................................................................43  
16. PUBLICATION AND DISCLOSURE POLICY  .......................................................44  
17. REFERENCES  ...........................................................................................................45  
LIST OF TABLES  
Table 1:  Emergency Contact Information ...................................................................................4  
Table 2:  Abbreviations and Specialist Terms .............................................................................9  
Table 3:  Schedule of Assessments  ............................................................................................21  
Table 4:  Investigational Product ...............................................................................................24  
Table 5:  PK Sampling & Imaging Timepoints  .........................................................................30  
Table 6:  Clinical Laboratory Tests  ...........................................................................................32  
Table 7:  Classification of 18F-DCFPyL Imaging Result and Histopathology Result for 
Cohorts A and B Separately .......................................................................................36  
LIST OF FIGUR
ES 
Figure 1:  Study Schema  .............................................................................................................20  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 9 
2. LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS
The following abbreviations and specialist terms are used in this study protocol. 
Table 2: Abbreviations and Specialist Terms  
Abbreviation or Specialist Term  Explanation 
AE adverse event  
ALT  alanine aminotransferase (SGPT)  
AST  aspartate aminotransferase (SGOT)  
AUC  area under the time- concentration curve  
BP blood p ressure  
BUD  beyond use date 
BUN  blood urea nitrogen 
CBC complete blood count  
CFR Code of Federal Regulations 
CL total body clearance  
CMP  comprehensive metabolic panel  
Cmax maximum (peak) serum concentration  
CRF  case report form 
CT computed tomography 
DMC  Data Monitoring Committee  
DoB  date of birth  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EOS  End of Synthesis 
FDA Food and Drug Administration 
18F Fluorine-18 
FDG Fluorodeoxyglucose 
68Ga Gallium -68 
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act of 1996 
hr Hour(s) 
HR Heart Rate  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 10 
Table 2: Abbreviations and Specialist Terms 
Abbreviation or Specialist Term  Explanation 
IB Investigator’s Brochure  
ICF Informed Consent Form 
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IND Investigational New Drug  
IRB Institutional Review Board  
IV Intravenous  
JHU Johns Hopkins University 
kg Kilogram  
m Minute/Meter  
mAb  Monoclonal Antibody 
MBq  MegaBequerel  
mCi MilliCurie  
MDP  methylene diphosphonate bone scan 
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram 
mL Milliliter 
MRI  Magnetic Resonance I maging  
MRT  Mean Residence T ime 
mSv millisievert  
N/A not applicable 
NCCN  National Comprehensiv e Cancer Network  
NCI National Cancer Institute  
CTCAE  Common Terminology Criteria for Adverse Events 
ng nanogram 
nM nanometer 
NOAEL  No Observed Adverse Effect Level  
NPV negative predictive value  
PET/CT positron emission tomography–computed tomography 
PI Principal Investigator 
PK pharmacokinetics  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 11 
Table 2: Abbreviations and Specialist Terms 
Abbreviation or Specialist Term  Explanation 
PLND  Pelvic lymph node dissection 
PPV Positive Predictive Value 
PSA Prostate  Specific Antigen  
PSMA  Prostate -Specific Membrane Antigen  
PT Preferred Term  
RBC Red Blood Cell count 
RCC Renal  cell carcinoma 
RP radical prostatectomy  
RR respiratory rate  
SAE  Serious Adverse Event  
SAP statistical analysis plan  
SD Standard deviation 
SoC/ SOC  Standard of Care/System Organ Class  
SOP Stand ard Operating Procedures 
SUV max Maximum Standardized Uptake Value  
SUV peak Peak standardized uptake value  
SUV r ratio to reference tissue standardized uptake value  
TIAC  Time -Integrated Activity coefficients  
US United States 
Vss Volume of Distribution at Steady S tate 
WBC White Blood Cell count 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 12 
3. INTRODUCTION
3.1. Background  Information
Prostate cancer is the most common cancer among men in the U nited States (US)  with an 
estimated number of new cases of 161,360 annually; it also represents the second most common 
cause of cancer -related death in men .1  The vast majority of men dying of prostate cancer 
succumb to metastatic, recurrent disease.  Thus imaging modalities that can detect, monitor, and 
restage residual, recurrent locoregional disease, and metastatic disease are highly desirable.  
Conventional anatomic and functional imaging including contrast-enhanced computed 
tomography (CT), [99mTc] methylene diphosphonate (MDP) bone scan, ultrasound, or magnetic 
resonance imaging (MRI) may not be sufficiently sensitive and specific for detection of prostate 
cancer lesions .2-5 
Tumors typically exhibit abnormally high metabolism and this mechanism has been exploited for 
imaging cancers.  Positron emission tomography (PET) employing 2 -deoxy -2-[18F]fluoro -D-
glucose (FDG PET), the clinical sta ndard for a number of cancers, has demonstrated mixed 
results in imaging prostate cancer .6-9  Other tumor metabolism- based approaches tested in 
prostate cancer (and other cancers) are the use of labeled choline to take advantage of the 
increased expr ession of choline kinase (ChKα) in tumor cells10, or increased uptake of amino 
acids such as methionine or leucine.  11C choline was approved by FDA in 2012; however, the 
sensitivity of 11C chol ine tends to be limited in extraprostatic lesions .11-14  Most recently, 
synthetic L -leucine analog trans ‐1‐amino ‐3‐18F‐fluoro ‐cyclobutane carboxylic acid (18F‐FACBC; 
Axumin®) was approved for use in men with suspected recurrence of prostate cancer . 
A number of new, targeted PET tracers have been introduced for imaging prostate cancer .15-20  
Proving particularly effective are low -molecular -weight agents that bind to the prostate- specific 
membrane antigen (PSMA), which is highly expressed in castration- resistant, metastatic prostate 
cancer .21,22,23  A novel, high specific activity, highly selective, low- molecular weight PSMA -
targeted PET radiotracer, 18F-DCFPyL, is currently being investigated as an imaging agent for 
prostate cancer at Johns Hopkins University School of Medicine (JHU).  The purpose of the current study is to further the clinical development of 
18F-DCFPyL to support marketing 
approval. 
3.2. Rationale for Developing Prostate Cancer Imaging Agents  
Prostate cancer is a significant public health problem affecting more than 2.3 million men in the 
US and another 4 million in Europe.  Annually, nearly 161,360 new cases of prostate cancer are 
diagnosed in the US , coupled with approximately 400,000 newly diagnosed c ases in Europe.1,24  
It is estimated that the disease will affect one in seven men in their lifetimes, leading to 
approximately 293,000 deaths per year in developed countries worldwide .25  The mortality from 
the disease is second only to lung cancer in men .1  An estimated $8 billion is currently spent 
annually in the US on surgery, radiation, drug therapy and minimally invasive treatments .26 
Several imaging modalities are currently employed for the diagnosis, staging and prognosi s of 
prostate cancer metastases.  Conventiona l cross -sectional imaging with CT and MRI rely on 
anatomical changes (lesions >1 cm), often resulting in missed lymph node metastases and low 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 13 
sensi tivity.  Nodal enlargement of metastases occurs relatively late in the progression of prostate 
cancer and neither CT nor MRI are effective at detecting the often microscopic lymph node 
metastases at the earliest stages of disease progression.  Additionally, nodal enlargement can also be caused by infection or inflammat ion, thereby reducing the specificity.  Meta- analyses of 24 
published studies revealed that CT and MRI performed equally poorly in the detection of lymph node metastases from prostate cancer.  Results of pooled sensitivity and specificity were 42% and 82%, respectively, for CT and 39% and 82%, respectively, for MRI.  Thus, the reliance on 
either CT or MRI may misrepresent the patient’s true status regarding nodal metastases, and 
misdirect the therapeutic strategies offered to the patient.
27  Radionuclide bone scans are 
commonly used for monitoring bone metastases.  However, as bone scans detect tissue 
remodeling, as opposed to tumor burden, false positives can be caused by inflammation, previous 
bone injuries, and arthritis, especially in older men .28  Therefore, new agents that will detect and 
localize the primary tumor, as well as small metastatic lesions, with high sensitivity and 
specificity are essential to more accurately diagnose and stage the disease, and monitor therapy.  
3.3. Targeting PSMA for Prostate Cancer Detection  
Prostate -specific membrane antigen (PSMA), also known as folate hydrolase I (FOLH1) or 
glutamate carboxypeptidase II (GCPII), is a trans -membrane, 750-amino acid type II 
glycoprotein primarily expressed in normal human prostate epithelium at very low levels, if at 
all, but is upre gulated in prostate cancer, including metastatic disease.  PSMA is a unique 
exopeptidase with reactivity toward poly- gamma -glutamated folates that is capable of 
sequentially removing the poly- gamma -glutamyl termini.29,30  Since PSMA is expressed by 
virtually all prostate cancers and its expressi on is further increased in poorly differentiated, 
metastatic and hormone- refractory prostate carcinomas, it is a very attractive target for 
developing agents for the diagnosis and staging of this disease .31,32,33  In addition to high 
expression in malignant prostatic tissue and being directly related to tumor aggressiveness ,34 
PSMA has also been detected in renal proximal tubules, in cells of the intestinal brush border 
membrane, in rare cells in the colonic crypts, in brain, salivary glands ,23,31,35,36 and in the 
neovasculature of nonprostatic solid carcinomas (e.g., renal cell, breast, colon, pancreas, 
melanoma, and lung carcinoma) .21 
A radiolabeled anti -PSMA monoclonal antibody (mAb) 7E11, marketed as Indium 111 
ProstaScint® (capromab pendetide) is currently being used to detect prostate cancer nodal metastasis and recurrence.  ProstaScint was first approved for marketing by the FDA in 1996, and while still available today, it is rarely used in practice due to a number of logistical and 
clinical limitations.  Furthermore, ProstaScint targets the intracellular domain of PSMA and is 
therefore thought to bind mostly necrotic portions of the prostate tumor .
32 
More recently, radiolabeled monoclonal antibodies that bind to the extracellular domain of 
PSMA have been devel oped and have been shown to accumulate in PSMA-positive prostate 
tumors in animals .30  Early promising results in man from various phase 1 and 2 tria ls have 
utilized PSMA as a therapeutic target.37,38  While monoclonal antibodies hold promise for tumor 
detection and therapy, there has been relatively limited clinical success outside of hematological 
cancers due to their low permeability in  solid tumors and slow clearance from the circulating 
blood pool.  Sma ller molecular weight compounds with higher permeability into solid tumors are 
likely to provide a distinct and definitive advantage in achieving higher percent uptake per gram 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 14 
of tumor tissue and a high percentage of specific binding.  Small molecul es are also expected to 
have improved blood clearance and tissue distribution in normal tissues compared with 
antibodies, thus enhancing the target- to-background and thereby making lesion detection more 
conspicuous. 
In the past few years, a number of investigational PSMA- targeted small molecules have been 
synthesized and labeled with various radioisotopes to be tested for use as imaging agents for 
prostate cancer.  A SPECT agent, 99mTc-MIP-1404, is currently in phase 3 testing for the 
detection of clinically significant prostate cancer in patients with low grade disease .39,40  PET 
imaging agents, such as 124I-MIP-1095, 18F-DCFCBC, 18F-DCFPyL, and 68Ga-HBED -CC, have 
also generated much interest for their potential use in detecting metastatic prostate cancer.  68Ga-
HBED -CC (68Ga-PSMA) has been broadly studied in the clinical setting at academic centers.  In 
a retrospective analysis of patients with high -risk localized disease prior to radical 
prostatectomy, 68Ga-PSMA PET/CT imaging showed a sensitivity of approximately 93% for 
intraprostatic lesions and 33% for regional lymph node metastases.  Specificity, positive and predictive values for lymph nodes were 100%, 100% and 69%, respectively .
41  A retrospective 
evaluation of data from 68Ga-PSMA PET/CT imaging in patients with biochemical recurrence of 
prostate cancer showed high detection rates, even in patients with low (0.2 to <0.5 ng/m l) PSA 
(58%).42  Studies have also been conducted to compare 68Ga-PSMA PET/CT and 18F-choline 
PET/CT imaging in prostate cancer.  In patients with re current prostate cancer scheduled to 
undergo salvage lymphadenectomy (thus providing histopathology as the truth standard), 68Ga-
PSMA PET/CT showed better performance than 18F-choline PET/CT with a significantly higher 
negative predictive value (NPV) and a ccuracy for the detection of locoregional recurrent and/or 
metastatic lesions prior to salvage lymphadenectomy, with sensitivity of 71% vs 87%, specificity of 87% vs. 93%, and accuracy of 83% vs 92%, respectively .
43  In patients with biochemical 
recurrence of prostate cancer with a negative [18F]-choline PET/CT, 68Ga-PSMA -PET/CT 
identified sites of recurrent disease in 43.8% of the patients with negati ve F-choline PET/CT 
scans .44  Another study was conducted to compare the detection rate of two PSMA -targeted 
PET/CT imaging agents side -by-side (18F-DCFPyL and 68Ga-PSMA) in patients with recurrence 
of prostate cancer .45  The results showed that 18F-DCFPyL PET/CT provided high image quality 
and visualized small prostate lesions with excellent sensitivity.  Furthermore, F -18 tracers in 
general offer important advantages over Ga-68 tracers, including higher production capacity 
from the use of a cyclotron as opposed to depending on the supply from Ga generators, and 
higher image resolution due to the intrinsic physical properties of F-18 (lower positron emission energy compared to Ga-68).  Thus, overall, 
18F-DCFPyL PET/CT may represent a promising 
alternative to 68Ga-PSMA PET/CT for imaging prostate cancer.  
PyL is a radiolabeled PSMA -targeted small molecule discovered at JHU that was in -licensed by 
Progenics in 2015.  It is currently being studied in phase 1 and phase 2 clinical trials under 
JHU’s IND 121,064 for the detection of primary and metastati c prostate c ancer.  In collaborati on 
with JHU, Progenics plans to complete the clinical development program of PyL and eventually 
seek FDA approval of PyL for the detection of prostate cancer.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 15 
3.4. 18F-DCFPyL  
18F-DCFPyL Injection is a radiolabeled small molecule that binds to the extracellular domain of 
PSMA with high affinity.  PSMA is a transmembrane glycoprotein expressed by virtually all 
prostate cancers, and its expression is further increased in metastatic an d hormone- refractory 
prostate carcinomas, which makes it a useful target for developing agents for the diagnosis and 
staging of prostate cancer.  
The nonclinical studies conducted with DCFPyL and 18F-DCFPy L included biochemical activity, 
biodistribution in xenograft mice, small animal PET imaging, and a s ingle dose IV toxicology 
study in rats.  Data from enzyme inhibition assay showed that DCFPyL binds competitively to 
PSMA expressing LNCaP cells with a Ki of 1.1 nM.  Studies in PSMA positive tumor bearing 
nude mice demonstrated significant tumor uptake and retention, coupled with a rapid clearance 
from non-target organs to provide support for the further development of 18F-DCFPyL as a 
radiopharmaceutical fo r detection and localization prostate cancer in man.  Results from a 14 -day 
single dose rat toxicology studies with DCFPyL resulted in a no observed adverse effect level 
(NOAEL ) of 0.5 mg/kg, the highest dose tested.  The maximum human mass dose of DCFPyL is 
expected to be 4 µg; thus, this represents an estimated safety margin of >1200-fold the human 
equivalent dose.  
Several investigator -initiated clinical studies with 18F-DCFPyL Injection in prostate cancer, as 
well as non -prostate cancer, are currently on going at Johns Hopkins University u nder IND 
121,064.  As of March 2016, 18F-DCFPyL Injection has been administered to a total of 108 
subjects at doses averaging 9 ± 1 mCi per injection.  Preliminary safety and efficacy data from 
two of these studies (J1418, J1545) are currently available. 
Study J1418 is a first in human, phase 1/2 study, conducted to evaluate the radiation dosimetry, 
biodistribution, metabolism, and safety of 18F-DCFPyL Injection with PET/CT imaging in men 
with metastatic prostate cancer.  Once safety was established, the utility of 18FDCFPyL PET/CT 
imaging to detect local, nodal, and/or metastatic prostate cancer was assessed in men with advanced prostate cancer .   
Study J1545, a phase 2 single-center, open-label study in men diagnosed with biochemical recurrence of prostate cancer.  The study was conducted to evaluate the safety of 
18F-DCFPyL 
Injection, to determine the location of putative sites of metastatic d isease by 18F-DCFPyL 
PET/CT, to correlate findings on 18F-DCFPyL PET/CT with conventional imaging, and to assess 
treatment response by 18F-DCFPyL PET/CT following six months of standard of care therapy. 
Data from these clinical studies at JHU demonstrate that PET imaging with 18F-DCFPyL 
Injection is feasible and safe.  Biodistribution following administration of 18F-DCFPyL Injection 
and optimal imaging time point were determined and radiation dose used was within limit for diagnostic radiotracers for PET.  Physiologic accumulation of 
18F-DCFPyL was found to 
correspond to the distribution of PSMA expressing organs.  Accumulation in primary tumor and metastatic lesions was very high, suggesting that 
18F-DCFPyL Injection can be used to 
prospectively detect resi dual tumor as well as regional or distance metastases with high 
sensitivity and specificity.   
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 16 
Safety results from all ongoing studies at JHU to date indicate that 18F-DCFPyL Injection is well 
tolerated, with no reported serious adverse events in any of the s tudies thus far.  A total of 6 
adverse events have been reported, one of which was attributed as possibly related to study drug 
(Grade 1 Headache).  
Progenics has obtained authorization from JHU to reference, and incorporate by reference, the data from the phase 1 and phase 2 studies conducted under the JHU IND.  Based on the 
promising results from these clinical studies, Progenics plans to initiate the current phase 2/3 
study (PyL 2301) under a new, separate IND to investigate the safety and efficacy of PyL 
imaging in patients with prostate cancer.  
3.5. Rationale for Dose Selection  
Prior to the first- in-human study with PyL (Study J1418) at JHU, human dosimetry was 
extrapolated from a preclinical biodistribution study in xenograft mice .46  The mouse organ 
activity concentrations in %ID/g were converted to the human %ID/ organ by setting the ratio of organ %ID/g to whole- body %ID/g in the mouse equal to that in humans and then solving for the 
human %ID/organ.  The adult male phantom organ masses listed in the OLINDA/EXM 1.0 were 
used for the conversion.  The human source organ time- activity curves were fitted using a 
monoexponential function.  Because the biodistribution data were radioactive decay- corrected, 
only the biological removal constants were obtained from the curve fits, and the physical decay constant for F-18 was added in obtaining the time- integrated activity coefficients  (TIAC).  The 
source organ TIACs in MBq-h/MBq were entered in the OLINDA/EXM 1.0 for the dose 
calculations.  The dynamic voiding bladder model was used to obtain the TIAC for the urinary 
bladder contents.  The whole- body clearance half -life (obtained as th e sum of sampled tissues, 
excluding the tumors) was used as the half- life to describe urinary bladder filling.  All 
radioactivity was assumed to be eliminated via the urine.  A one hour voiding interval was assumed.  
The urinary bladder wall was projected t o be the organ with the highest absorbed dose.  To limit 
the radiation -absorbed dose to the urinary bladder (≤ 50 mGy), the highest human dose is 
estimated to be 8.95 mCi.  As a result, the first- in-human dose used at JHU for obtaining basic 
information re garding the metabolism (including kinetics, distribution, and localization) was 
determined to be ≤9 mCi.  The 9 mCi administered dose of 
18F-DCFPyL Injection  results in a 
comparable radiation dose to that of other radiotracers used in oncology such as [18F]-FDG.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 17 
4. TRIAL OBJECTIVES AND  PURPOSE
4.1. Primary Objective
The primary objective of the study is t o assess the diagnostic performance of 18F-DCFPyL 
PET/CT imaging to determine the presence or absence of metastatic disease in  pre-prostatectomy 
patients with high  risk prostate cancer  (cohort A)   
4.2. Secondary O bjectives 
1.To evaluate the safety and tolerability of 18F-DCFPyL
2.To assess the diagnostic performance of 18F-DCFPyL PET/CT imaging to determine the
presence or absence of prostate cancer within sites of metastasis or local recurrence
(cohort B)
3.To determine detection rates of 18F-DCFPyL PET/CT and conventional imaging among
lesion locations (e.g., bone, lymph nodes, soft tissue, prostate gland)
4. To determine positive and negative predictive value (PPV and NPV) of 18F-DCFPyL
PET/CT imaging
5. To determine the pharmacokinetics, biodistribution, and excretion of 18F-DCFPyL
4.3. Exploratory Objective s 
1.To assess 18F-DCFPyL uptake among lesion locations (e.g., bone, lymph nodes, soft
tissue, prostate gland)
2.To assess the relationship between 18F-DCFPyL uptake in prostatic and extraprostatic
lesions with  baseline PSA  and testosterone levels , and Gleason Score at time of radical
prostatectomy
3.To assess the diagnostic performance of 18F-DCFPyL PET/CT imaging to detect prostate
cancer within the prostate gland (cohort A)
4.To assess the  impact of 18F-DCFPyL PET/CT imaging on clinical management plans
5. To determine the PPV of 18F-DCFPyL PET/CT imaging for  lesions detected by PET that
are outside the planned surgical template or biopsy site
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 18 
5. TRIAL E NDPOINTS
5.1. Primary Endpoints
1.Specificity of 18F-DCFPyL PET/CT imaging to determine the absence of metastatic
prostate cancer  within the pelvic lymph nodes relative to histopathology (cohort A)
2.Sensitivity of 18F-DCFPyL PET/CT imaging to determine the presence of metastatic
prostate cancer within the pelvic lymph nodes relative to histopathology (cohort A)
5.2. Secondary Endpoints 
1. Safety and tolerability (Cohorts A and B combined):
a. Treatment -emergent adverse events
b. P re- and post-18F-DCFPyL PET/CT lab values, ECGs and vital signs
2.Sensitivity of 18F-DCFPyL PET/CT imaging to de tect prostate cancer within sites of
metastasis or local recurrence relative  to histopathology (Cohorts B)
3. Comparison of detection rates (Cohorts A and B combined) for lesion counts overall and
by  location (i. e., bone, lymph nodes, soft tissue, prostate gland ) between  18F-DCFPyL
and conventional imaging
4.PPV and NPV of 18F-DCFPyL PET/CT imaging (Cohort A) to predict prostate cancer
within the prostate gland  and lymph nodes
5.PPV of 18F-DCFPyL PET/CT imaging to predict prostate cancer within sites of local
recurrence and other metastatic lesions (c ohort B )
6.Pharmacokinetic parameters [e.g., Cmax, area under the cur ve (AUC), total clearance
(CL), steady -state volume of distribution (V ss) and mean residence time (MRT) ] (subset
of Cohorts A and B combined)
5.3. Exploratory Endpoints 
1.18F-DCFPyL uptake in different lesion locations (i.e., bone, lymph nodes, soft tissue,
prostate gland) as defined by SUV peak, SUV max, SUV r results derived from central
readers , compared to histopathology (cohorts A and B)
2.To assess the relationship between SUV peak, SUV max and SUVr in prostatic and
extraprostatic lesions  with each of the following:  baseline PSA, baseline testosterone
level, and Gleason Score at  time of radical prostatectomy
3.Sensitivity and specificity of 18F-DCFPyL PET/CT imaging to detect prostate cancer
within the prostate gland relative to histopathology (c ohort A)
4.Changes to clinical management plan based on a review of clinical and radiographic
subject data before and after 18F-DCFPyL PET/CT imaging by a central panel of disease
experts using a structured questionnaire
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 19 
5.PPV of 18F-DCFPyL PET/CT imaging in subjects  with corresponding histopathology that
is outside the planned protocol surgical template or biopsy site
6. INVESTIGATIONAL PLAN
6.1. Overall Study Design
This is an open-label, non-randomized, Phase 2/3, multi- center study designed to evaluate the 
safety and diagnostic performance of 18F-DCFPyL PET/CT imaging to determine the presence or 
absence of metastatic prostate cancer  in subjects with at least high risk prostate cancer  who are 
planned for radical prostatectomy [RP] with pelvic lymph node dissection [ PLND ]) (cohort A), 
and subjects with radiologic evidence of local recurrence or new or progressive metastatic 
disease (cohort B). 
Eligible subjects (see Section  7.1 for Inclusion Criteria) will be enrolled in a non -randomized, 
sequential manne r, with competitive enrollment between study sites.   
Diagnostic performance characteristics of 18F-DCFPyL PET/CT imaging will be evaluated using 
histopathology as the truth standard.  See Section  8.4 for details on blinding.  
The study will explore changes to clinical management plans based on data before and after 18F-
DCFPyL PET/CT imagin g.  
This study is planned to be performed in approximately 10 sites in the United States  and Canada.  
See Figure 1  and Table 3 for the study schema and schedule of assessments.   
6.2. Number of Subjects 
Approximately 377 subjects are planned to be dosed in this study:  
•Approximately 262 subjects will be dosed in Cohort A.
•Approximately 115 subjects will be dosed in Cohort B.
See Section  7 for complete eligibility details and Section  12.1 for complete sample size 
assumptions. 
6.3. Treatment Assignment  
All subjects will be administered 9 ± 1 mCi (333 ± 37 MBq) 18F-DCFPyL Injection followed by 
PET/CT imaging as illustrated in  the schema below.  See Section  9.6 Study Drug Administration 
and Table 3 Schedule of Assessments for complete details .   
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 20 
Figure 1: Study Schema 
6.4. Dose Adjustment Criteria 
Dosing adjustments of 18F-DCFPyL Injection are not permitted.   
6.5. Study Duration  
The duration of subject participation will be from informed consent through 18F-DCFPyL 
PET/CT scanning and follow-up visit, a total maximum duration of 58 days.   
6.6. Safety Monitoring  
An independent Data Monitoring Committee (DMC) will not be used for this open label study.  
Howeve r, safety monitoring will consist of continuously monitoring adverse events on an 
ongoing basis in accordance with Section  11.  A Safety Review Committee, consisting of 
Sponsor representatives (e.g. , Medical Monitor, Clinical Operations designee, Biometrics 
designee) and at least one active Principal Investigator  will also review data on an ongoing basis 
to assess subject safety , eligibility and baseline characteristics through listings, tables and subject 
profiles.  
6.7. Criteria for Study Termination  
The Sponsor reserves the right to terminate the study at any time. In the event of serious, 
unexpected and related adverse events, the pro gram may be sto pped prematurely upon advice 
from the Safety Review Committee, the Sponsor or upon request from the FDA.  In addition, the 
Sponsor or the Institutional Review Board (IRB) or Ethics Committee (EC) may terminate an 
investigational site for the  following (but not limited to) reasons:  
•If any safety issues occur;
•Failure of the Investigator to comply with pertinent International Conference onHarmonisation (ICH) E6 guidelines on Good Clinical Practice (GCP) guidelines and
regulations;
•If serious protocol violations occur;

Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 21 
•Submission of knowingly false information from the research facility to the Sponsor,
Clinical Monitor, or other party involved in the study;
•Failure of the Investigator to enroll subjects into the study at an acceptable rate asagreed -upon with the Sponsor
Table 3: Schedule of Assessments  
Screening
/ Baseline  18F-
DCFPyL 
Dosing 18F-
DCFPyL 
Imaging Pre-
Surgery/Biopsy 
Follow-Up 
Day-30 to 
Day 1 Day 1 1-2 Hours
Post
DosingWithin 28 Days 
Post Dosing 
Cohorts A and B 
Informed Consent & Eligibility X 
Demographics (date of birth, race, 
ethnicity , height, weight , BMI) X 
Medical History  (see Section  11.1.1)   X 
Prior Cancer Medications & 
Treatments  X 
Clinical Labs (Hematology, 
Chemistry)  see Table  6  X1 X 
PSA (Total)  & Testosterone X1 
Vital Signs (B lood P ressure , Heart 
Rate, Temperature, R espiratory Rate) X X 
(pre-
dosing)  X 
(pre-
imaging)  X 
12-Lead E lectrocardiogram (E CG)
(see Section  11.1.4)X 
(pre-
dosing)  X 
(pre-
imaging)  
18F-DCFPyL Administration  (see 
Section  9) X 
Whole B ody PET/CT (see 
Section  10.1) X 
Adverse Events (see 
Section  11.2.1.1 )  X X5 
Concomitant Medications (see 
Section  8.2) X X X 
Conventional I maging (CT  or MRI, 
Bone Scan)  (see Section  10.1)  X2 
Surgery or Image -Guided Biopsy X3,6 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 22 
Table 3: Schedule of Assessments  
Screening
/ Baseline  18F-
DCFPyL 
Dosing 18F-
DCFPyL 
Imaging Pre-
Surgery/Biopsy 
Follow-Up 
Day-30 to 
Day 1 Day 1 1-2 Hours
Post
DosingWithin 28 Days 
Post Dosing 
Subset of Cohort A or B at Johns Hopkins University only for Pharmacokinetic (PK) 
Analysis 
Blood C ollection   X (9 
collections)4 
Urine Collection  X (3 
collections)4 
Whole B ody PET/CT  X (3 
scans)4 
1 To be collected prior to dosing, if collected on day of dosing.   If PSA and testosterone ha ve not been tested within 30 
days of study drug injection, a blood draw will be collected prior to dosing.  
2 If not obtained as standard of care ≤  6 weeks (Cohort A) or ≤ 4 weeks (Cohort B) prior  to Day 1.  Na-18F-PET bone 
scans conducted at screening must be at least 10 hours prior to dosing (see Section 7.2 ).   
3 Surgery or biopsy to occur  at least 12 hours from time of 18F-DCFPyL  dosing but not more than 28 days from 
dosing.  In Cohort B, imaging used to guide biopsy (i.e.,  CT, MRI) will be submitted  to a central core imaging lab.  
4 See Section  10.6  for complete details. Analysis should occur immediately following last sample collected.  
5 A safety phone  call will also occur 7(±3)  days post -dosing [if surgery  (Cohort A)  or biopsy  (Cohort B) has not yet 
occurred ] and 21(±7)  days post biopsy  (Cohort B).   See Section  11.2.1.1  for complete details.  
6  If a subject’s planned procedure  (RP or biopsy)  for prostate cancer changes following 18F-DCFPyL imaging, the 
alternate or additional prostate cancer procedure and corresponding histopathology data will be recorded in the 
electronic case report form ( eCRF ).
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 23 
7. SELECTION AND WITHDR AWAL OF SUBJECTS
7.1. Subject Inclusion Criteria
Subjects must meet all of the following inclusion criteria:  
All Cohorts:  
1. Adults ≥18 years of age.
2.Subjects  provide signed informed consent and confirm that they are able and willing to
comply with all protocol requirements.
3.Histologically confirmed adenocarcinoma of the prostate.
Cohort A Only: 
4.At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016 (clinical
stage ≥T3a or PSA >20 ng/mL or Gleason score ≥8) .47
5. Scheduled or
 will be scheduled to undergo radical prostatectomy with PLND.
Cohort B Only: 
6.Radiologic evidence of local recurrence or new or progressive metastatic disease
demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan(
99mTc-MDP or Na18F) within 4 week s of Day 1 .
7.If prior treatment with radiation or ablative therapy, evidence of recurrence outside the
confines of prior treated site(s) .
8.Scheduled  or will be scheduled  for percutaneous biopsy of a t least one amenable lesion.
7.2. Subject Exclusion Criteria  
Subjects meeting any of the following exclusion criteria are not eligible for this study:  
All Cohorts:  
9.Subjects administered any  high energy (>300 KeV) gamma- emitting  radioisotope within
five physical half -lives , or any IV iodinated contrast medium within 24 hours, or any high
density oral contrast medium (oral water contrast is acceptable)  within 5 days, prior to
study drug injection.
10.Subjects  with any medical condition or other circumstances that, in the opinion of the
investigator, compromise obtaining reliable data, achieving study objectives, orcompletion.
Cohort A Only: 
11. Patients with prior androgen deprivation therapy or any investigational neoadjuvant agent
or intervention
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 24 
Cohort B Only: 
12.Prior radiation or ablative th erapy to intended site of biopsy , if within the prostate bed .
13. Initiation of new systemic therapy for recurrent and/or progressive metastatic disease
since radiographic documentation of recurrence/ progression.
7.3. Subject Withdrawal Criteria 
A patient may withdraw from the study at any time for any reason without prejudice to his/her 
future medical care by the physician or at the study site.  Likewise, the Investigator and/or  
Sponsor have the right to withdraw patients from the study.  Subjects may be disco ntinued for 
any of the following reasons: 
•Significant protocol violation or noncompliance ( e.g., initiation of treatments
forbidden per  Section 7.2)
•Adverse event that precludes further study participation
•Best medical interest of the patient (Investigator decision )
•Sponsor terminates the study
•Subject requests to be withdrawn from the study
•Subject is lost to follow -up
•Death
Should a subject withdraw, all efforts will be made to complete the required study procedures as 
thoroughly as possible.   
Data will be collected for all withdrawn subjects up until the time of discontinuation.  The reason 
for discontinuation from the study will be recorded in the subject’s eCRF.   
8. TREATMENT OF SUBJECTS
8.1. Description of Study Drug
A single administration of 18F-DCFPyL Injection (PyL) will be administered 1 -2 hours prior to 
PET/CT imaging on Day 1 . 
Table 4: Investigational Product  
Investigational Product  
Product Name  18F-DCFPyL INJECTION (PyL)  
Dosage Form  Sterile solution for intravenous injection  
Unit Dose  9 ± 1 mCi (333 ± 37 MBq)  
Route of Administration  Intravenous catheter placed in an antecubital vein or an equivalent 
venous access  
Physical Description  Colorless, particle -free solution 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 25 
8.2. Concomitant Medications and Procedures  
All concomitant medications and medical procedures that occur within 7 days of consent will be 
recorded.  
Any new prostate cancer therapy is strictly prohibited from time of dosing (Day 1) to surgery 
(Cohort A), or from time of radiographic documentation of disease progression to biopsy (Cohort 
B).  If a subject reports having received a new prostate cancer therapy (e.g., hormone, drug, 
biologic, radiologic, or chemotherapy) or alternate medical procedure(s) for prostate cancer, 
during these time periods, the subject  should be discontinued from the study.   
Medical procedure(s) and histopathology data for subjects who do not receive the planned 
protocol procedure but who received alternate or additional medical procedure(s) for prostate 
cancer will be recorded in the eCRF . 
8.3. Treatment Compliance  
All 18F-DCFPyL drug injected will be administered under the supervision of the investigator, or 
qualified designee.  Details of the study drug injection will be captured in each subject’s source documents.  
8.4. Randomization and Blinding  
This is  an open- label , non-randomized study.  Three independent readers from a central imaging 
core lab will be given access to 18F-DCFPyL PET/CT  imaging , conventional imaging, and 
biopsy- guided imaging .  The central readers will be blinded to all other clinical information and 
radiology assessments.  Likewise,  the Investigator is responsible for ensuring that local 
pathologists who generate the histopathology results for the primary endpoint remain blinded to 
all imaging results.    
9. STUDY DRUG MATERIALS AND MANAGEMENT
9.1. Study Drug
Please reference Section  8.1 for a description of the study drug. 
9.2. Restrictions 
9.2.1. Food and Fluid Intake  
There are no dietary or food restrictions for this trial. 
Increased fluid intake should occur before and after image acquisition to maintain proper 
hydration throughout the study period and decrease radiation exposure to the urinary bladder.  To 
enhance imaging, subjects should be encouraged to void post study drug injection and prior to imaging.  
Subjects should follow pre -imaging and preoperative guidelines as per institutional practices and 
in accordance with standard of care principles.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 26 
9.2.2. Activity 
The radioactivity administered in this study is similar to other diagnostic radiopharmaceuticals 
and should be managed according to institutional policies.   
9.3. Study Drug Packaging and Labeling  
The final drug product (18F-DCFPyL) is a clear, colorles s injectable solution at a strength of 5-
75 mCi/mL ( 185-2775 MBq/mL) 18F-DCFPyL at End of Synthesis (EOS).  18F-DCFPyL will be 
dispensed and filled into a unit-dose syringe.  The final drug product will be placed into  a lead 
pig and delivered to the clinical site in shipping containers with lead shielding.  
Labels will be generated according to local policies and meet minimum requirements for labeling 
radioactive materials in compliance with federal, state, and local pharmacy regulations.  
Progenics minimum requirem ents for the syringe label will include  the following :  subject 
identifier, product name, dispensing lot number, ordered dose, dispense date/time, dispensed 
activity and volume, and beyond use date (BUD).  An auxiliary sticker reading “New Drug —
Limited by Federal Law to Investigational Use” shall be affixed to the unit-dose container. 
9.4. Study Drug Storage  
The study drug  should be maintained  at room temperature within th e received lead shield unit-
dose system until time of  administration.    
9.5. Study Drug Preparation  
The final drug product is supplied to each institution on the day of administration  in a unit-dose 
syringe  with no additional preparation required. Institutional policies and standard operating 
procedures (SOPs)  should be followed for receipt and appropriate radiation safety handling.  
Before and after each administration , measure the amount of radioactivity in the syringe using an 
appropriate dose calibrator. Apply decay correction if necessary and calculate the administered dose accordingly.  
9.6. Administration  
Please see the Imaging Manual for complete details  including pre -and post- injection 
measurement of the 18F-DCPyL Injection dose syringe.  Administration must occur by the 
labeled expiration time.  
1.Place an intr avenous catheter in an antecubital vein or an equivalent venous access .
2. Ensure patency of the line with a saline flush.
3.Inject a bolus of 9±1  mCi (333±37 MBq) of 18F-DCPyL  into the IV line or equivalent
venous access by slow  push from the appropriately shielded syringe according to normal
local practices .
4. Administer an intravenous flush (e.g. , 5-10 ml sterile Sodium Chloride Injection, 0.9%),
to ensure full delivery of the dose.
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 27 
If dose extravasation is noticed during or after completion of the drug adm inistration:  
1. Try to aspirate as much extravasated drug as possible through the still- intact catheter .
2. Imaging should proceed unless contraindicated for safety reasons.
3. Examine the skin area for local toxicity before discharge, and instruct subject to conta ct
site immediately if  local symptoms at injection site do not improve or worsen.
4.Note the event as an Adverse Event in the CRF and notify the Sponsor within 24 hours.
9.7. Study Drug Accountability  
In accordance with ICH and FDA requirements, the investigator  and/or drug dispenser must at 
all times account for all study drug furnished to the institution and prepared for the patient, 
whether used or unused.   
No study agent is to be used outside of this study.  A ccurate and adequate accountability records  
must be maintained  by the radiopharmacy, hot lab or nuclear medicine department responsible 
for receipt and dispensation of study drug.  Records should include at minimum: 
•Dates of receipt, lot number and quantities received from Sponsor or designee;
•Dates, sub ject numbers, and amount dispensed for administration to specific subjects;
•If applicable, dates, lot numbers, and drug quantities destroyed.
The investigator is responsible for ensuring that study agents are administered only to subjects 
included in this study in accordance with the study protocol. 
Throughout the study, drug accountability will be performed by appropriate Sponsor personnel 
and when appropriate, reconciliation will be performed. 
9.8. Study Drug Handling and Disposal  
18F-DCFPyL Injection is a rad ioactive drug and should be handled by personnel trained in the 
proper use and disposal of radiopharm aceuticals according to institutional policies and applicable 
regulations or guidance.  When handling and administering 18F-DCFPyL Injection, follow 
aseptic procedures and use effective radiation shielding, and appropriate safety measures to 
minimize radiation exposure.   
Empty or unused product should be decayed at the site  according to institutional policies and 
applicable state and federal regulations.   Record the use and/or decay of study agent on the Drug 
Accountability record.   
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 28 
10. ASSESSMENT OF EFFICACY
10.1. Image Acquisition  
10.1.1. 18F-DCFPyL PET/CT (all cohorts) 
18F-DCFPyL PET imaging will be performed on local PET/CT scanners with CT for correction 
of physical effects (e.g., attenuation, scatter) and anatomic localization.   
At 1-2 hours post 18F-DCFPyL injection, the subject will be asked to void, and a whole body CT 
and PET scan  will be acquired  from the mid -thigh through the vertex of the skull .  Parameters f or 
PET/CT scanning can be found in the Imaging Manual .   
10.1.2. Bone Scan (all cohorts) 
A radionuclide bone scan (either 99mTc-MDP or 18F-NaF PET/CT, depending upon the site’s 
standard of care) will be obtained at Screening if one has not been obtained within six  weeks 
(Cohort A) or four weeks (Cohort B) prior to study drug injection.  If conducted as part of 
Screening, 18F-NaF PET  bone scan s must be done at least five physical half -lives ( 10 hours) 
prior to  18F-DCFPyL  injection.  Bone scan images will be submitted to the independent central  
imaging core lab  per in struction in the Imaging Manual  for assessment . 
10.1.3. CT or MRI  (all cohorts) 
A contrast -enhanced CT of the chest, abdomen and pelvis (or non- contrast CT chest with 
Gadolinium-enhanced MRI of the abdomen and pelvis for subjects who have a medical 
contraindication to iodinated contrast) will be obtained at Screening if not already obtained 
within 6 weeks (Cohort A) or 4 weeks (Cohort B) prior to study drug injection.  If CT is 
conducted at  Screening, IV iodinated contrast medium cannot be administered within 24 hours of 
study drug injection.  H igh density oral contrast medium (oral water contrast is acceptable) 
cannot be administered within 5 days prior to study drug injection.  Copies of baseline CT or MR images will be submitted to the independent central imaging core lab per instruction in the Imaging Manual  for assessment.  
10.1.4. Biopsy Guided Imaging  (cohort B only) 
In Cohort B, imaging used to guide biopsy (i.e., C T/MRI ) will be collected and reviewed 
centrally  to confirm the biopsy location in the area of interest.   The instruction for capturing 
biopsy images and directions for submitting the images to the independent central imaging core 
lab will be found in the Image Guided Biopsy Manual . 
10.2. Image Interpretation  
An independent imaging core lab will receive and evaluate 18F-DCFPyL PET/CT  baseline, 
conventional images, and imaging used to guide biopsy (i.e., CT , MRI).  The processes for 
image acquisition, transmittal and interpretation are detailed in the Imaging Manual  and Imaging 
Review Charter documents.    
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 29 
10.3. Prostatectomy and Lymphadenectomy  
Within 28 days post-study drug injection, all subjects in Cohort A will undergo standard of care 
RP with PLND as detailed in the Surgical Manual .  Extent of PLND will be captured in the 
eCRF.  
Surgical staff will label all specimens removed during surgery to correlate with the specific 
anatomic location of removal, in accordance with the Surgical Manual .   
Should a subject receive alternate or additio nal procedure(s) for prostate cancer after dosing , the 
procedure and corresponding histopathology data will be recorded in the eCRF.   
10.4. Interventional Radiology  
Up to two  lesions (one bone and one soft-tissue lesion, wherever feasible) may be biopsied in 
cohort B, within 28 days following 18F-DCF PyL imaging.  If more than one lesion is obtained, 
the interventional radiolog ist will identify the specimen to be evaluated for diagnostic assessment 
and statistical analysis.  The lesions most preferred for biopsy will be those that are suspicious on 
all or most imaging modalities  and are in the investigators judgement safe for biopsy.  The final 
biopsy site will be decided in consultation with the Interventional Radiology servi ce for 
feasibility.   Details regarding the collection of imaging used to guide biopsy ( e.g., X-ray, CT, 
MRI ) and transmittal to the central imaging lab can be found in the Image Guided Biopsy 
Manual .  Images will be reviewed centrally to confirm uptake of 18F-DCF PyL in the area of 
interest.  
Should a subject receive alternate or additional procedure(s) for prostate cancer  after dosing , the 
procedure and corresponding histopathology data will be recorded in the eCRF.  
10.5. Biopsy and Surgical Pathology 
Immediately  following biopsy or surgery, the specimens will be sent for histopathological 
processing and analysis at the site in accordance with the study Pathology Manual .   
Gross handling of the prostate gland and lymphadenectomy specimens, if applicable, will include 
whole gland assessment and sectioning of the entire prostate gland, overall measurement of specimen size, lesion location, dissection and description (including location) of identified lymph 
nodes, and submission of lymph nodes in their entirety plus all remaining fibroadipose tissue for 
each harvested regional packet.  Histopathology results of the prostate gland and pelvic lymph 
nodes (Cohort A) or biopsy location (Cohort B) will be recorded in the eCRF.  
Should a Cohort A subject forego RP surger y and undergo alternative p rocedure for prostate 
cancer (e. g., biopsy), the procedure and corresponding histopathology data will be recorded in 
the eCRF.  Likewise, should a Cohort B subject receive additional procedure for prostate cancer , 
the procedure and corresponding histopathology data will be recorded in the eCRF.  
10.6. Pharmacokinetics 
A total of 10 subjec ts from either cohort at the JHU site will complete  the pharmacokinetics (PK) 
portion of the study.  For detailed instructions on sample collection, processing, and analysis, 
please refer to the PK Manual . 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 30 
A 4.5 mL  blood sample will be collected at the following nine time  points:  pre-dose, 5±2 m, 
15±2 m, 30±5 m, 1±0.25 hr, 2±0.25 hr, 4±0.25 hr, 6±0.25 hr, and 8±0.25 hr post -dose.   
Urine samples will be collected over the following intervals: 0 -2 hr, 2-4 hr and 4-8 hr post dose. 
Whole body PET/CT scans will be collected at three time points:  up to 17 minutes after PyL 
injection  and prior to voiding, 1± 0.25 hr and 4± 0.25 hr post dose. 
Table 5: PK Sampling & Imaging Timepoints  
Procedure Pre- 
dose 0 
hr 5±2 
m 15± 2 m 30± 5 m 1± 0.25 hr 2± 0.25 hr 3± 0.25 hr 4± 0.25 hr 6± 0.25 hr 8± 0.25 hr 
18F-DCFPyL  
Administration  X 
Blood & Plasma Collection  X X X X X X X X X 
Urine Collection  <-----------X ----------- > < -----X -----> <- -----X ------ > 
18F-DCFPyL 
PET/CT Imaging  X X X 
Analysis will be generated as described below and in Section  12.5.4.  Aliquots of blood, plasma 
and urine samples will be batch counted in an automated gamma counter immediately following 
the sample collection  period.  Resulting raw radioactivity counts will be converted into 
radioactivity concentrations using an aliquot of the dosing formulation as a reference standard.   
Blood concentration- time data will be computed by non -compartmental analysis and 
pharmacokinetic paramet ers, e.g., C max, AUC, CL, Vss, and MRT will be generated.  Ratios of 
blood to plasma radioactivity at each time point will be calculated.  
The total amount of excreted radioactivity per urine collection interval will be calculated as a 
product of urine radioactivity concentration and volume, and then expressed as a percent of 
administered dose.  
Metabolic profiles in urine will be determined using radio-chromatographic methods.  The areas 
under the radio- chromatographic peaks corresponding to the parent compounds and putative 
metabolites, if applicable, will be used in the qualitative assessment of metabolic profiles in 
urine. Whole-body PET/CT images acquired immediately  after PyL injection  and at 1 hr and 4 hr post-
dose will be used to obtain volumes and activity concentrations  for selected tissues/ organs.  
Based on these data, time-integrated activity coefficients will be derived and may be used for 
subsequent calculation of radiation absorbed doses using the OLINDA/EXM software.   This 
analysis will be described in a dosimetry report for 
18F-DCFPyL.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 31 
11. ASSESSMENT OF SAFETY
11.1. Safety Parameters  
11.1.1. Demographic/Medical History  
Demographic and baseline information, including date of birth, race, and ethnicity, will be 
collected.   
A complete prostate medical history will be obtained at the first screening visit.  Prostate medical 
history includes review of prostate disease history, prostate cancer stagin g, PSA results, biopsy 
results, and all past/present therapies.   
Other clinically relevant medical history will be collected  prior to study drug administration.  
This should include any past and/or current medical conditions that, in the opinion of the 
investigator, are clinically relevant regardless of whether it has resolved.  Special attention should 
be paid  to prior malignancies other than prostate cancer or concurrent or past conditions that can 
change pelvic anatomy or cause lymphadenopathies (e.g., viral, bacterial or parasitic infections ). 
11.1.2. Vital Signs  
Vital sign measurements will include temperature, respiratory rate, blood pressure , and heart 
rate.  All measurements should be obtained from the subject in the sitting position and measured at two inte rvals on the day of dosing, including pre- dosing and pre- imaging.  
11.1.3. Weight and Height 
Height , weight , and BMI at screening will be captured . 
11.1.4. Electrocardiogram (ECG)  
A 12 -lead electrocardiogram (ECG) will be taken at two intervals on the day of dosing, including 
prior to dosing and prior to imaging.  Please refer to the ECG Procedure Manual for acquisition 
and transmittal details.  The onsite Investigator has the responsibility to evaluate the ECG for the 
assessment of subject safety.  Adverse events wil l be reported in the CRF.   
11.1.5. Laboratory Assessments 
11.1.5.1. Hematology, Blood Chemistry, PSA and Testosterone  
A blood draw will be collected at the screening and follow-up visits as stated in  Table 6.  
Clinical hematology and blood c hemistry will be evaluated for safety monitoring.  If PSA and 
testosterone have not been tested within 30 days of study drug injection, a blood draw will be 
collected prior to dosing. 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 32 
Table 6: Clinical Laboratory Tests 
Category Analytes Frequency 1 
Hematology  CBC:  WBC differential (neutrophils, 
lymphocytes, monocytes, eosinophils, basophils), 
WBC count, RBC count, Hematocrit, 
Hemoglobin, Platelets  Screening, Follow -Up 
Chemistry  CMP:  Sodium, Potassium, Calcium, Chloride, 
Glucose, BUN, Creatinine, Total Bilirubin,  ALT, AST, Alkaline Phosphatase, Albumin, Total Protein  Screening, Follow -Up 
PSA Total  Screening  
Testosterone Total  Screening  
CBC=complete blood count; WBC=white blood cell; RBC=red blood cell; CMP=comprehensive metabolic panel; 
BUN=blood urea nitrogen; ALT=alanine aminotransferase; AST=aspartate aminotransferase; PSA=prostate -specific 
antigen  
1 Blood draws and laboratory testing will be conducted according to local standard practices.   PSA and testosterone 
resulted within 30 days of Day 1 does not need to be re -tested.  
11.2. Adverse and Serious Adverse Events  
11.2.1. Definition of Adverse Events  
11.2.1.1. Adverse Event (AE)  
An AE is the development of an undesirable medical occurrence or the deterioration of a pre-
existing condition following or during exposure to a pharmaceutical product, whether or not 
considered related to the product.   
All AEs (related and unrelated) will be collected  on the day of , after  18F-DCFPyL dosing and at 
time of follow -up visit (pre-surgery/biopsy) .  Adverse events will also be assessed  via a safety 
phone call at the following timepoints, if applicable:  1) 7 (±3) days post study drug injection ( if 
surgery or biopsy has not yet occurred), and 2) 21 (±7) days post biopsy.   
All AEs,  whether or not they are related to study drug , must be recorded on the study case report 
forms .  
11.2.1.2. Serious Adverse Event (SAE)  
A serious adverse event is an AE that fulfils one or more of the following: 
•Results in death
•It is immediately life -threatening
•It requires in -patient hospitalization or prolongation of existing hospitalization
•It results in persistent or significant disability or incapacity
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 33 
•Results in a congenital abnormality or birth defect of a subject ’s child
•It is an important medical event that may jeopardize the patient or may require
medical  intervention to prevent one of the outcomes listed above.
All SAEs that occur after any patient/subject has been dosed until study completion , whether or 
not related to the study, must be recorded on forms provided by the Sponsor, or designee. 
11.3. Relationship to Study Drug  
The Principal Investigator or Sub-Investigator must make the determination of relationship to the 
investigational product for each AE (Unrelated or Related).  The Investigator should decide whether, in his or her medical judgment, there is a reasonable possibility that the event may have 
been caused b y the investigational product.  If no valid reason exists for suggesting a 
relationship, then the AE should be classified as “unrelated.”  If there is any valid reason, even if 
undetermined, for suspecting a possible cause- and-effect relationship between the investigational 
product and the occurrence of the AE, then the AE should be considered “related.” 
11.4. Recording Adverse Events  
Adverse events spontaneously reported by the patient/subject and/or in response to an open question from the study personnel or re vealed by observation will be recorded during the study at 
the investigational site.   
The investigator should assess all clinical laboratory results for clinical significance and rec ord 
the assessment in source documents.  The investigator should evaluate any laboratory result 
change from pre - and post- study drug administration to determine if the change meets the 
definition of an AE or SAE.  Record any clinically significant lab resu lts determined to meet the 
definition of an AE and SAE on the AE eCRF and SAE Report Form, respectively. 
Information about AEs and SAEs will be collected from the first administration of study drug  
until the pre-surgery/biopsy follow-up visit .  The AE term  should be reported in standard 
medical terminology and be the medical diagnosis when possible.  For each AE, the investigator 
will evaluate and report the onset (date and time), resolution (date and time), intensity, causality, 
action taken, serious outcome (if applicable), and whether or not it caused the patient to discontinue the study . 
Intensity will be assessed according to the NCI CTCAE, version 4.03.  If the CTCAE grading is 
not defined in the NCI CTCAE grading table for a particular AE, severity wi ll be rated according 
to the following definitions 
•Mild (awareness of sign or symptom, but easily tolerated)
•Moderate (discomfort sufficient to cause interference with normal activities)
•Severe (incapacitating, with inability to perform normal activities)
•Life Threatening (immediate risk of death from the event as it occurred)
•Death (death related to adverse event)
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 34 
It is important to distinguish between serious and severe AEs.  Severity is a measure of intensity 
whereas seriousness is defin ed by the criteri a under Section  11.2.1.2.  An AE of severe intensity 
may not be considered serious. 
Should a pregnancy occur, it must be reported and recorded on the Sponsor ’s pregnancy form.  
Pregnancy in itself is not regarded as an AE.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or 
congenital abnormality) must be followed up and documented even if the patient was 
discontinued from the study. 
All reports of congenital abnormalities/birth defects are SAEs.  Spontaneous miscarriages should 
also be reported and handled as SAEs.  Elective abortions without complications should not be 
handled as AEs. 
11.5. Reporting Serious Adverse Events  
All SAEs (related and unrelated) will be recorded at the same interval defined for AE collection 
as indicated in Section  11.2.1.1 .  Any SAEs considered possibly or probably related to the 
investigational pr oduct and discovered by the Investigator at any time after the study should be 
reported.  All SAEs must be reported to Progenics or designee within 24 hours of the first 
awareness of the event.  The Investigator must complete, sign and date the SAE pages, verify the accuracy of the information recorded on the SAE pages with the corresponding source 
documents, and send a copy by email or fax to Sponsor, or designee.   
Additional follow-up information, if required or available, should promptly be emailed or  faxed 
to Sponsor, or designee via  a follow-up SAE form and placed with the original SAE information 
and kept with the appropriate section of the CRF and/or study file. 
Progenics  Pharmaceuticals, Inc. is responsible for notifying the relevant regulatory authorities of 
certain events.  It is the Principal Investigator’s responsibility to notify the IRB or IEC of all 
SAEs that occur at his or her site.  Investigators will also be notified of all unexpected, serious, 
drug- related events (7/15 Day Safety Repo rts) that occur during the clinical trial.  Each site is 
responsible for notifying its IRB or IEC of these additional SAEs. 
12. STATISTICS
12.1. Sample Size  
Approximately 262 subjects will be dosed in cohort A.   N o formal power calculations will be 
performed  for cohort B ; reliable estimates should be achievable from approximately 115 dosed.  
This resul ts in a total sample size of approximately 377 subjects dosed in the study.   
The primary analysis  in Cohort A will test the co -primary endpoints of sensitivity and specificity 
of 18F-DCFPyL PET imaging relative to histopathology  for metastatic disease  in pre-
prostatectomy patients .  For each co -primary endpoint there will be three independent imaging 
readers .  At least two of the three readers must reject the null hypothesis for specificity  to be 
deemed a success.  If specificity is a success , then the same two readers need to reject the null 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 35 
hypothesis for sensitivity to reach overall success of the primary endpoint.  The null hypotheses 
will be tested in the following order:  
1.Specificity of 18F-DCFPyL PET/CT imaging relative to histopathology in cohort A
H0: πSp = 0.80 versus H 1: πSp ≠ 0.80,
2.Sensitivity of 18F-DCFPyL PET/CT imaging relative to histopathology in cohort A
H0: πSe = 0.40 versus H 1: πSe ≠ 0.40
where π Se is the true sensitivity and π Sp is the true specificity of 18F-DCFPyL PET imaging. 
A total of approximately 262 subjects from Cohort A will provide 80% power to reject the null 
hypothesis about sens itivity at the 5% significance level if the true sensitivity is at least 60% and 
at least 80% power to reject the null hypothesis about specificity at the 5% significance level if the true specificity is at least 87.8%.  These calculations are based on the following assumptions:    
•the probability of a positive histopathology sample  in Cohort A is 20%,
The sample size is based on the normal approximation to the binomial distribution without a 
continuity correction
48:  
𝑛 ≥ �𝑧𝛼/2�𝑃0(1−𝑃0)+𝑧𝛽�𝑃1(1−𝑃1)
𝑃1−𝑃0�2
P0 are P 1 are values of sensitivity under the null and alternative hypotheses, respectively.   
After adjusting sensitivity and specificity separately by their corresponding prevalence values, a 
total in 2 36 evaluable subjects  are needed  in cohort A.  Assuming 10% drop out or non- evaluable 
rate increases the required number of subjects in cohort A to approximately 262.  
The type I error rate of 5% will be preserved by requiring that both null hypotheses be rejected in 
order to draw the conclusion that 18F-DCFPyL is efficacious for imaging. The second primary 
endpoint is only tested if the first primary endpoint is rejected at 5% per a fixed sequential 
method.  If the first hypothesis fails to be rejected, no further testing will be conducted.  
12.2. Analysis Populations  
12.2.1. Screened  Subjects  
All subjects who sign an informed consent document will be included in the screened  subject 
population. 
12.2.2. Safety Set  
All subjects who receive any amount of 18F-DCFPyL will be included in the  safety set.  
12.2.3. Evaluable Set 
Evaluable subjects  in Cohort A are those who provide a 18F-DCFPyL PET image result (positive 
or negative) and a corresponding RP histopathology result (positive or negative).   
Evaluable subjects  in Cohort B are those who provide a 18F-DCFPyL PET image result  (positive 
or negative) and a corresponding biopsy histopathology result (positive or negative for each 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 36 
subject ), along with a conventional image that confirms the location of the histopathology 
sample.  
12.2.4. Per Protocol Set 
The per protocol  set is the evaluable set, excluding subjects with  major protocol deviations 
impacting efficacy endpoint(s) . 
12.2.5. PK Evaluable Set 
Subjects who provide at least six of the nine scheduled blood samples will be evaluable for PK 
analysis of blood samples.  Subjects with at least two of the three scheduled urines will be evaluable for PK analysis of urine samples.  
12.3. Endpoints and Derivations  
12.3.1. Sensitivity, Specificity, PPV, and NPV 
Table 7 will be used to classify th e combined pelvic lymph node packets (left or right) from 
Cohort A and biopsy from Cohort B according to its 18F-DCFPyL image result (positive or 
negative) generated from central imaging review and its histopathology result (positive or 
negative for prostate cancer ) generated by the sites’ patholog y review .    Nodes identified on 18F-
DCFPyL PET/CT images in areas that were not removed in surgery for Cohort A will not be 
tabulated due to absence of histopathology. 
Table 7: Classification of 18F-DCFPyL Imaging Result and Histopathology Result for 
Cohorts A and B  Separately  
Histopathology Result 
18F-DCFPyL Image Positive* Negative 
Positive  TP FP I(p) 
Negative  FN TN I(n) 
R(p) R(n)  N1 
TP=true positive; FP=false positive; FN=false negative; TN=true negative.   
R(p) and R(n) denote the subject s with a  positive or negative  lobe or biopsy , respectively, based on histopathology.  
I(p) and I(n) denote the subject s with a positive and negative lesion , respectively, based on the 18F-DCFPyL image.  
N1 indicates the number of subject s with evaluable pelvic lymph node packets from  Cohort A  or the number of 
subject s with evaluable biopsies  from Cohort B. 
*Positive histo patho logy should be for prostate cancer only.
The following statistics will be computed: 
•Sensitivity = TP/R(p),
•Specificity = TN/R(n),
•Positive predictive value (PPV) = TP/I(p),
•Negative predictive value (NPV) = TN/I(n ).
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 37 
For Cohort A, a true positive or true negative must be determined from imaging and 
histo pathology aligning  on outcome overall. 
12.3.2. Lesions Per Subject  
The number of lesions detected on the 18F-DCFPyL PET/CT image in each of bone, lymph 
nodes, soft tissue, and prostate gland will be determined by each of the three central imaging core lab independent readers.  The number of lesions per subject per region will be computed for 
each subject based on each reader’s lesion count.  
12.3.3. Change from Baseline 
For laboratory da ta, baseline will be the screening/baseline value.  Change from baseline will be 
computed as the pre- surgery/biopsy follow -up value minus the baseline value +1 . 
For ECG data, baseline will be the pre-dose value.  Change from baseline will be computed as the post-dose value minus the pre-dose value +1 . 
For vital signs, baseline will be the pre -dose value.  Change from baseline will be computed as 
the post-dose value minus the pre- dose value +1 and the pre-surgery/biopsy value minus the 
basel ine value +1. 
12.3.4. Pre-Treatment and Concomitant Medications 
Pre-treatment medications are those administered prior to 
18F-DCFPyL administration; 
concomitant medications are those administered from 18F-DCFPyL administration through last 
study visit.   
12.3.5. Treatment -Emergent Adverse Events  
Treatment -emergent adverse events will be those observed from the day of 18F-DCFPyL 
administration until 7 (±3) days post study drug injection [ if surgery (Cohort A) or biopsy 
(Cohort B) has not yet occurred] and 21 (±7) days post biopsy in Cohort B .   
12.4. Missing Data  
No imputation of missing data will be applied.  
12.5. Analyses 
In general, continuous endpoints will be summarized by visit using summary statistics: sample 
size, mean, standard  deviation, median, minimum, and maximum.  Categorical endpoints wil l be 
summarized by visit using frequencies and percentages.  
12.5.1. Subject Characteristics  
A disposition table will be presented to show how many subjects were screened, the number and 
percentage of subjects in each population set, study completers, and early dis continuations along 
with reasons for dis continuation.  
Baseline characteristics (age in years, categorical age [<65 years, ≥65 years], race, gender, 
ethnicity, height [cm], weight [kg], BMI [kg/m2]) will be summarized for all analysis  population 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 38 
sets.  Medical history verbatim terms will be coded using Medical Dictionary for Regulatory 
Activities (MedDRA ).  Subject frequencies and percentages will be tabulated by system organ 
class (SOC) and preferred term (PT) for all analysis population set s.  Prior prostate cancer 
medical history will be summarized for all analysis  populations.  Type of CT, MRI or bone scans 
will be summarized along with days each occurred prior to study drug administration  by all 
analysis  populations. 
Medications will be coded using t he WHO Drug Dictionary .   Pre-treatment medications will 
each be summarized by ATC4 class and generic name for all analysis  population set s.   
12.5.2. Efficacy Analysis 
12.5.2.1. Primary Endpoint  
Cohort A 
The primary analysis in Cohort A will be addressed by computing point estimates and 95% two-
sided confidence intervals (CIs) for specificity  first and if the null hypothesis is rejected for 
specificity then sensitivity will be tested next.   Both outcomes are on the subject  level  (one 
overall  outcome per subject) in the evaluable set.   If the per protocol  population exists then this 
analysis will be performed on the per protocol population as a supplemental analysis.   The 
normal approximation to the binomial distribution will be used .  Sensitivity and specificity will 
be computed for each of thre e central imaging core lab independent readers.  
The null hypothesis for s pecificity  will be rejected if the lower limit of the 95% CI exceeds 0.80 
for at least  two readers .  If statistical significance is achieved  for specificity where the null 
hypothesis is  rejected , then sensitivity will be tested where the null hypothesis will be rejected if 
the lower limit of 95% CI exceeds 0.40 for the same two readers who rejected the null hypothes is 
for specificity .  
A sensitivity analysis will be performed to allow any 2 of the 3 central readers to reject the null 
hypothesis for sensitivity only after specificity has been deemed a success. This analysis will not 
require the same 2 central readers to reject the null hypothesis for specificity and sensitivity. This 
analysis will be performed for the evaluable and per protocol populations. 
12.5.2.2. Secondary Endpoints  
The following secondary efficacy  endpoint analyses will be generated on the evaluable set .  
Point estimates and two -sided 95% CIs will be presented for the following secondary endpoints:   
•PPV and NPV will be computed for the pelvic lymph node packets (one observation
per subject for cohort A).
•Sensitivity of 18F-DCFPyL PET/CT imaging within sites of metastasis or local
recurrence rel ative to histopathology (cohort B)
•PPV will be computed for the biopsies (one observation per subject for cohort B).
The normal approximation to the binomial distribution will be used for endpoints having one observation per subject.  The null hypothesis will be rejected for each if the lower limit of the 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 39 
95% CI exceeds 0.50 for at least 2 of the 3 central readers. Statistics will be computed for each 
of the three central imaging core lab independent readers.  
Lesion s per subject, as detected by 18F-DCFPyL PET/CT and conventional images will be 
summarized for each tissue type (bone, lymph nodes, soft tissue, and prostate gland) and each of the three central imaging core lab independent readers using evaluable subjects  from both 
cohorts.   
12.5.2.3. Exploratory Analyses 
Analyses will be generated on the evaluable s et for the following exploratory endpoints: 
•The number of lesions per subject will be plotted against baseline PSA and baseline
testosterone for each of the three central imaging core lab independent readers using
evaluable subjects from both cohorts.
•SUV
max, SUV peak and SUVr will be summarized for each tissue type (e.g., bone, lymph
nodes, soft tissue, and prostate gland) and each of the three central imaging core lab
independent readers using evaluable subjects from both cohorts.  The relationship
between SUVr in prostatic lesions and baseline PSA and testosterone levels, and Gleason
score at time of radical prostatectomy will be evaluated.
•Sensitivity, SUV max, SUV peak, and SUV r will be computed for the following subgroups in
Cohort A:
- Previous radiation therapy (yes/no)
- Previous hormonal therapy (yes/no)- Previous chemotherapy (yes/no)
•SUV
max, SUV peak, and SUV r will be summarized with positive and negative
histopathology.  Each will be summarized by Gleason s core for the single or dominant
prostate tumor nodule.
•The clinical management plans before and after review of 18F-DCFPyL PET/CT scans
will be summarized.
An e xploratory analysis of PPV of 18F-DCFPyL PET/CT imaging in subjects who are excluded 
from the evaluable s et but have corresponding histopathology outside the planned protocol 
procedure will be performed on the s afety set. 
12.5.3. Safety 
All safety parameters will be presented for the safety set . 
12.5.3.1. Exposure 
Volume administered (mL) and activity administered (mCi) will be summarized using th e Safety 
Set and the E valuable Set. 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 40 
12.5.3.2. Adverse Events  
Adverse event verbatim terms will be co ded using MedDRA.  The frequency and percentage of 
subjects with an adverse event and the number of events will be summarized by SOC and PT.  
Adverse events will also be summarized by severity and, separately, by relationship to treatment.  Serious adverse events, adverse events leading to study discontinuation and adverse events 
leading to death will be listed.  
12.5.3.3. Clinical Laboratory 
Observed values and changes will be tabulated using summary statistics in the safety set . 
12.5.3.4. ECG 
Observed values and changes will be tabulated for each visit using summary statistics.  Shift 
tables comparing pre- to post -dosing categorical ECG values will be presented using the safety 
set. 
12.5.3.5. Vital Signs  
Observed values and changes will be tabulated using summary statistics in the safety set . 
12.5.4. Pharmacokinetics  
Mean (±SD) and individual activity- time plots will be presented for blood (mCi/mL), urine (% 
injected dose excreted per collection interval ) and selected organs/tissues, including “whole 
body” (% injected dose at each scanning time -point ).  Summary statistics (sample size  [N], 
arithmetic mean, geometric mean, median, SD, minimum, and maximum) will be presented by 
timepoint for each of blood, urine and selected organs/tissues, including “whole body”.   
Summary statistics will be presented for C
max, area under the curve ( AUC ), total clearance ( CL), 
steady-state volume of distribution (V ss), and mean residence time ( MRT ) for the subset of 
subjects (PK evaluable set) . 
13. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS
Data collected during this study may be used to support the development, registration or 
marketing of 18F-DCFPyL.  All data collected during the study will be controlled by Progenics or 
designee and Progenics will abide by a ll relevant data protection laws .   
The investigator will grant monitor(s) and auditor(s) from Progenics or its designee and regulatory authority(ies) access to the subject’s original medical records for verification of data 
entered into the eCRF and to audit the data collection process.  The subject’s confidentiality will be maintained and will not be made publicly available to the extent permitted by the applicable 
laws and regulations. 
13.1. Study Monitoring  
Before an investigational site can enter a patient i nto the study, a representative of Sponsor will 
visit the investigational study site to: 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 41 
•Determine the adequacy of the facilities
•Discuss with the investigator(s) and other personnel their responsibilities with regard
to protocol adherence, and the responsibilities of Progenics or its representatives.
This will be documented in a Clinical Study Agreement between Progenics, or
designee and the investigator.
During the study, a monitor from Progenics or designee  will have regular contacts with the 
investigational site, for the following:  
•Provide information and support to the investigator(s)
•Confirm that facilities remain acceptable
•Confirm that the investigational team is adhering to the protocol, that data are being
accurately recorded in the case report forms, and that investigational productaccountability checks are being performed
•Perform source data verification.  This includes a comparison of the data in the case
report forms with the patient’s medical rec ords at the hospital or practice, and other
records relevant to the study.  This will require direct access to all original records for
each patient (e.g. , clinic charts).
•Record and report any protocol deviations not previously sent to the Sponsor, ordesignee .
•Confirm AEs and SAEs have been properly documented on CRFs and confirm any
SAEs have been forwarded to the Sponsor, or designee, and those SAEs that met
criteria for reporting have been forwarded to the IRB.
•Confirm serious/unexpected/related SAE notification  letter( s) from the Sponsor have
been acknowledged and returned to the Sponsor.
The monitor will be available between visits if the investigator(s) or other staff needs 
information or advice. 
13.2. Audits and Inspections  
Authorized representatives of the Sponsor, a regulatory authority, an Independent Ethics 
Committee or an Institutional Review Board may visit the site to perform audits or inspections, 
including source data verification.  The purpose of a Sponsor audit or inspection is to 
systematically  and independently examine all study- related activities and documents to 
determine whether these activities were conducted, and data were recorded, analyzed, and 
accurately rep orted according to the protocol, Good Clinical Practice guidelines of the 
Intern ational Conference on Harmonization, and any applicable regulatory requirements.   
The investigator should c ontact Progenics immediately if contacted by a regulatory agency about 
an inspection, and will provide Progenics with the results of any such audits and with copies of 
any regulatory documents related to such audits. 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 42 
14. ETHICS
This clinical trial will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and that are consistent with GCP and applicable regulatory 
requirement(s).  The rights, safety, and we ll-being of the trial subjects are the most important 
considerations and should prevail over interests of science and society.  
14.1. Good Clinical Practice (GCP), Laws and Regulations  
The investigator must ensure that he/she and all authorized personnel for the study are familiar 
with the principles of Good Clinical Practice (GCP) and that the study is conducted in full 
conformity with the current revision of the Declaration of Helsinki, ICH Guidelines and applicable local laws and regulations, with the understanding that local laws and regulations take 
precedence over respective sections in the Declaration of Helsinki and/or the ICH Guidelines. 
14.2. Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC) Approval  
The final study protocol, including the final version of the Informed Consent Form, must be 
approved or given a favorable opinion in writing by an IRB or IEC as appropriate.  The investigator must submit documented approval to the Sponsor before he or she can enroll any 
patient/subject into the study.  
The Principal Investigator is responsible for informing the IRB or IEC of any amendment to the protocol in accordance with local requirements.  In addition, the IRB or IEC must approve all 
advertising used to recruit patients for the study.  The protocol must be re-approved by the IRB 
or IEC upon receipt of amendments and annually, as local regulations require. 
The Principal Investigator is also responsible for providing the IRB with reports of any 
reportable serious adverse drug reactions from any other study conducted with the investigational 
product.  The Sponsor, or designee, will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines. 
14.3. Written Informed Consent  
The Principal Investigator(s) at each center will ensure that the patient is given full and adequate 
oral and written informatio n about the nature, purpose, possible risk and benefit of the study.  
Patients must also be notified that they are free to discontinue from the study at any time.  The 
patient should be given the opportunity to ask questions and allowed time to consider the information provided. 
The patient’s signed and dated informed consent must be obtained before conducting any study 
procedures. 
The Principal Investigator(s) must maintain the original, signed Informed Consent Form.  A copy 
of the signed Informed Consent Form must be given to the patient.  
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 43 
14.4. Subject Confidentiality  
The Investigator must ensure that the subject’s privacy is maintained.  A subject should only be 
identified by their date of birth and subject number on the case report forms or other documents 
submitted to the Sponsor.  Documents that are not submitted to the Sponsor (e.g., signed 
informed consent form) should be kept in a strictly confidential section of the study file by the Investigator. 
Written authorization is to be obtained from each subject prior to enrollment into the study in 
accordance with the applicable privacy requirements [e.g., the Health Insurance Portability and Accountability Act of 1996 Standards for Privacy of Individually Identifiable Health Information 
(“HIPAA”) and any other s tate and country privacy requirements]. 
14.5. Financial Disclosure  
All investigators must provide financial disclosure information in accordance with the US Code 
of Federal Regulation s Title 21 CFR 54.2 through 54.6. 
15. DATA HANDLING AND RE CORDKEEPING
15.1. Case Report Forms and Study Records 
Progenics or designee will provide an electronic case report form (eCRF) and eCRF Completion 
Guidelines for the entry of study data.  eCRFs must be completed for each subject.  All study 
data must be reported accurately on eCRFs fro m original source data.  Source documents are 
original documents, data and records (e.g., hospital records, office charts, laboratory notes, 
memoranda, evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, magnetic media, diagnostic images, subject files).  The investigator will make available the source documents for inspection.  This information will be considered as 
confidential. 
The use of eCRFs will encompass electronic data entry, query management and investigat or 
approval.  Systems used for electronic data capture will be compliant with FDA regulations 21 
CFR Part 11 and within the constraints of the applicable local regulatory agency guidelines.  
The Investigator or designee will review, sign and date the compl eted eCRF sections.  This 
signature will indicate a thorough inspection of the data in the eCRF and will certify its content.  
15.2. Inspection of Records  
The Sponsor, or designee, will be allowed to conduct site visits to the investigation facilities for 
the purpose of monitoring any aspect of the study.  The Investigator agrees to allow the monitor to inspect the drug storage area, study drug stocks, drug accountability records, subjec t charts 
and study source documents, and other records relative to study condu ct.  See Section  13.2.  
15.3. Retention of Records 
The Principal Investigator must maintain all documentation relating to the study for a period of 2 
years after the last marketing application approval, or if not approved 2 years following the 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 44 
discontinuance of the test article for investigation.  If it becomes necessary for the Sponsor or the 
Regulatory Authority to review any documentation relating to the s tudy, the Investigator must 
permit access to such records.  No study document should be destroyed without prior written 
agreement between Sponsor and the investigator. 
16. PUBLICATION AND DISCLOSURE POLICY
All unpublished documentation [including the protocol, eCRF and Investigator Brochure (IB)] 
given to the investigator is strictly confidential.   All recipients must agree not to disclose the 
information herein contained to any person without the prior written authorization of Progenics.  
The submission of these documents to the IRB is expressly permitted.   
The investigator agrees that Progenics maintains the right to use the results of this study in their 
original form and/or in a global report for submission to governmental and regulatory authorities of any country. 
The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Progenics in accordance with the guidelines set forth in the applicable publication or financial agreement. 
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 45 
17. REFERENCES
1.Siegel R, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin . 2017;67:7-30.
2.Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal
ultrasonography: correlation of imaging and pathological examinations. J Urol.
1989;142:76–82.
3.Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical
assessment, CT, and MR imaging. Radiology. 1987;162:331–336.
4.Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-
dimensional proton MR spectroscopic imaging —clinicopathologic study. Radiology.
1999;213:473–480.
5.Blomqvist L, Carlsson S, Gjertsson P, et al. Limited evidence for the use of imaging todetect prostate cancer: a systematic review. Eur J Radiol. 2014;83:1601–1606.
6. Turlakow A, Yeung HW, Pui J, et al. Fludeoxyglucose positron emission tomography in
the diagnosis of giant cell arteritis. Arch Intern Med. 2001;161:1003–1007.
7. Hofer C, Laubenbacher C, Block T. Fluorine-18-fluorodeoxyglucose positron emission
tomography is useless for the detection of local recurrence after radical prostatectomy.Eur Urol. 1999;36:31–35.
8. Nunez R, Macapinlac HA, Yeung HW, et al. Combined 
18F-FDG and 11C-methionine
PET s cans in patients with newly progressive metastatic prostate cancer. J Nucl Med.
2002;43:46–55.
9. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial
findings of PET with 2- deoxy -2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751–756.
10. Ramírez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of
choline kinase is a frequent feature in human tumor-derived cell lines and in lung,
prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–
583.
11. Krause BJ, Souvatzpglou M, Tuncel M, et al. The detection rate of [11C]choline-
PET/CT depends on the serum PSA-value in patients with biochemical recurrence ofprostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23.
12. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]choline positron
emission tomography in patients with increasing prostate- specific antigen levels after
primary treatment for prostate cancer. BJU Int. 2007;100: 786–793.
13. Giovacchini G, Picchio M, Coradesschi E, et al. 11C-choline uptake with PET/CT for the
initial diagnosis of prostate cancer: relation to PSA  levels, tumor stage and anti-
androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065–1073.
14. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on
11C- choline PET/CT detection rate in patients with biochemical relapse after radical
prostatectomy. J Nucl Med. 2009;50:1394–1400.
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 46 
15. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary
perspective. Radiology. 2007;243:28–53.
16. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Positron emission tomography and
molecular imaging of the prostate: an update. BJU Int. 2006;97:923–931.
17. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the
evaluation after treatme nt of localized prostate cancer. Eur Urol. 2003;44:32–38.
18.Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission
tomography for re- staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-
positron emission tomography. J Urol. 2003;169:1337–1340.
19. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph- node metastases with
integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic
prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. EurUrol. 2007;52:423–429.
20.Greco C, Cascini GL, T amburrini O. Is there a role for positron emission tomography
imaging in the early evaluation of prostate cancer relapse? Prostate Cancer Prostatic Dis.2008;11:121–128.
21. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(Suppl
10):S13–S18.
22. Wright GL, Jr, Grob BM, Haley C, et al. Upregulation of prostate- specific membrane
antigen after androgen -deprivation therapy. Urology. 1996;48:326–334.
23. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate- specific
membrane antigen expression in normal and malignant human tissues. Clin Cancer Res .
1997;3:81–85.
24. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF, Sung JJ.
Global Incidence and Mortality for Prostate Cancer: Analysis  of Temporal Patterns and
Trends in 36 Countries. Eur Urol. 2016 70(5):862-874
25. Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global Burden of
Urologic Cancers, 1990-2013. Eur Urol. 2017 71(3):437-446..
26. Racioppi M, Palermo G, D’Addessi A, Pinto F, Sacco E, D’Agostino D, Vittori M, Bassi
PF. Hot topics in urological health economics. A mini review. Archivio Italiano diUrologia e Andrologia 2012; 84, 2.
27. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens
JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymphnodes in patients with prostate cancer: a meta-analysis. Clinical radiology. 2008 Apr
30;63(4):387-95.
28. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN,
Barre tt JA, Eckelman WC, Pomper MG, Joyal JL. Preclinical evaluation of novel
glutamate -urea-lysine analogues that target prostate- specific membrane antigen as
molecular imaging pharmaceuticals for prostate cancer. Cancer research. 2009 Sep
1;69(17):6932-40.
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 47 
29.Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B,
Heston WD. Prostate- specific membrane antigen: a novel folate hydrolase in human
prostatic carcinoma cells. Clinical Cancer Research. 1996 Sep 1;2(9):1445-51.
30.Smith -Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D,
Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for
the extracellular domain of prostate -specific membrane antigen. Cancer research. 2000
Sep 15;60(18):5237-43.
31. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito Jr PM, Wang CY, Haas GP.
Expression of prostate- specific membrane antigen in normal and malignant human
tissues. World journal of surgery. 2006 Apr 1;30(4):628-36.
32. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the
tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer.1998 Dec 1;83(11):2259-69.
33. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its
regulat ion in prostate cancer. Journal of cellular biochemistry. 2004 Feb 15;91(3):528-39.
34. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE,
Kuefer R, Rubin MA. Prostate- specific membrane antigen expression as a predictor of
prostate cancer progression. Human pathology. 2007 May 31;38(5):696-701.
35. Luthi- Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human
brain N- acetylated α-linked acidic dipeptidase (NAALADase). Journal of Pharmacology
and Experimental Therapeu tics. 1998 Aug 1;286(2):1020-5.
36. Trover JK, Beckett ML, Wright GL. Detection and characterization of the prostate ‐
specific membrane antigen (PSMA) in tissue extracts and body fluids. InternationalJournal of Cancer. 1995 Sep 4;62(5):552-8.
37.David KA, Milowsk y MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM,
Bander NH. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.Clinical genitourinary cancer. 2006 Mar 31;4(4):249-56.
38. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH.
Phase I trial of yttrium- 90—labeled anti —prostate- specific membrane antigen
monoclonal antibody J591 for androgen-independent prostate cancer. Journal of clinical
oncology. 2004 Jul 1;22(13):2522-31.
39.Hillier SM, Maresca KP, Lu G , Merkin RD, Marquis JC, Zimmerman CN, Eckelman
WC, Joyal JL, Babich JW. 99mTc- labeled small -molecule inhibitors of prostate -specific
membrane antigen for molecular imaging of prostate cancer. Journal of Nuclear
Medicine. 2013 Aug 1;54(8):1369-76.
40.Reinfeld er J, Kuwert T, Prante1 O, Wullich B, Hennig P, Beck M, Sanders J, Ritt P,
Schmidt D, Goebell P  First experience with PSMA -SPECT/CT using a 99mTc -labeled
PSMA inhibitor for patients with biochemical recurrence of prostate cancer J Nucl MedMay 1, 2015 vol. 56 no. supplement 3 67.
Clinical Protocol:  PyL -2301 
18F-DCFPyL  
Amendment 2: 06 Nov 2017 
Page 48 
41.Budaus L, Leyh -Bannurah SR, Salomon G et al. Initial experience of 68Ga- PSMA
PET/CT imaging in high -risk prostate cancer patients prior to radical prostatectomy. Eur
Urology 2015.
42. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kübler
H, Haberkorn U, Eisenhut M, Wester HJ. Evaluation of hybrid 68Ga-PSMA ligand
PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. Journalof Nuclear Medicine. 2015 May 1;56(5):668-74.
43.Pfister D, P orres D, Heidenreich A, et al. Detection of recurrent prostate cancer lesions
before salvage lymphadenectomy is more accurate with 68Ga- PSMA -HBED -CC than
with 
18F-Fluoroethylcholine PET/CT. European Journal of Nuclear Medicine and
Molecular Imaging. 2016 Mar 19:1-8.
44. Bluemel C, Krebs M, Polat B et al. 68Ga- PSMA PET/CT in patients with biochemical
prostate cancer recurrence and negative 18F-choline PET/CT. Clin Nucl Med 2016.
45. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M,
Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R. Comparison of [18F] DCFPyL and
[68Ga] Ga -PSMA -HBED -CC for PSMA -PET Imaging in Patients with Relapsed Prostate
Cancer. Molecular Imaging and Biology. 2015 Aug 1;17(4):575-84.
46. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S,
Sgouros G, Mease RC, Pomper MG. 2- (3-{1-Carboxy -5-[(6-[18F] fluoro -pyridine-3-
carbonyl) -amino]-pentyl}-ureido)- pentanedioic acid,[ 18F] DCFPyL, a PSMA -based PET
imaging agent for prostate cancer. Clin Cancer Res. 2011 Dec 15;17(24):7645-53.
47.Recent Updates to NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®).  NCCN website.
https://www.nccn.org/professionals/physician_gls/recently_updated.asp Accessed July12, 2016.
48. Fleiss JL, Levin B, Paik MC. The Measurement of interrater agreement. In: Statistical
methods for rates and proportions. 3
rd Ed. New York, NY: Wiley, 2003;29-33
49. Gönen M, Panageas KS, Larson SM. Statistical issues in analysis  of diagnostic Imaging
experiments with multiple observations per patient . Radiology 2001; 221:763-767